New biomarker HRG (Histidine-Rich Glycoprotein) that enables early diagnosis and severity assessment of sepsis

JRCT ID: jRCT1061220024

Registered date:04/06/2022

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Sepsis
• Date of first enrollment: 01/07/2022
• Target sample size: 150
• Study type: Observational

Outcome(s)

• Primary Outcome: Clinical performance (sensitivity, specificity) of differential diagnosis of sepsis by HRG

Secondary Outcome

1 Clinical performance (concordance) of differential diagnosis of sepsis by HRG
2 Relationship between HRG and prognosis

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1 Inpatients who visited the emergency outpatient department of Okayama University Hospital or a joint research institute between March 31, 2023 after the approval of the Institutional Review Board and met two or more qSOFA criteria
2 Patients who can voluntarily obtain consent to participate in the study in writing from the person or his / her surrogate

Exclude criteria

1 Under 18 years old
2 Pregnant woman
3 Patients after resuscitation with cardiopulmonary arrest
4 Patients transferred from another hospital
5 Patients who are considered inappropriate for study for other reasons

Related Information

• Primary Sponsor: Morimatsu Hiroshi
• Source(s) of Monetary Support: Japan Agency for Medical Research and Development